Chemoprevention; Complication; Inflammatory Bowel Disease; Neoterminal Ileitis; Surgery
Abstract :
[en] BACKGROUND & AIMS: Vitamin D deficiency is common in Crohn's disease (CD). High-dose vitamin D had anti-inflammatory effects in preclinical studies and trials of patients with CD. We performed a randomized trial to determine whether high-dose vitamin D prevents postoperative recurrence of CD after ileocolonic resection. METHODS: Patients with CD after ileocolonic resection with ileocolonic anastomosis were assigned randomly to groups given weekly 25,000 IU oral vitamin D (n = 72) or placebo (n = 71) for 26 weeks, at 17 hospitals in The Netherlands and Belgium, from February 2014 through June 2017. Patients were assessed at baseline and at weeks 2, 6, 12, and 26 for laboratory and clinical parameters, and underwent ileocolonoscopy at 26 weeks. The primary end point was endoscopic recurrence (modified Rutgeerts score, ≥i2b, as assessed by blinded readers) at 26 weeks. Secondary end points included clinical recurrence (Crohn's disease activity index, ≥220), quality of life (measured by the 36-Item Short Form Health Survey, Inflammatory Bowel Disease Questionnaire, and EuroQol, a 5-dimension questionnaire), and outcomes associated with the baseline serum concentration of vitamin D. RESULTS: In the vitamin D group, serum levels of 25-hydroxy vitamin D increased from a median of 42 nmol/L at baseline to 81 nmol/L at week 26 (P < .00001), whereas levels did not change significantly in the placebo group and remained unchanged at 43 nmol/L. In the intention-to-treat analysis, the proportion of patients with endoscopic recurrence at 26 weeks did not differ significantly between the vitamin D vs the placebo group (58% vs 66%; P = .37). The cumulative rate of clinical recurrence did not differ significantly between the groups (18.1% in the vitamin D group vs 18.3% in the placebo group; P = .91). Quality of life improved slightly over time in both groups, but did not differ significantly between groups (P = .07). There were few adverse events in either group. CONCLUSIONS: High-dose vitamin D, compared with placebo, did not reduce the incidence of postoperative endoscopic or clinical recurrence of CD in patients who underwent ileocolonic resection with ileocolonic anastomosis. ClinicalTrials.gov no: NCT02010762.
Kocovska, E., Gaughran, F., Krivoy, A., et al. Vitamin-D deficiency as a potential environmental risk factor in multiple sclerosis, schizophrenia, and autism. Front Psychiatry, 8, 2017, 47.
Holick, M.F., Vitamin D deficiency. N Engl J Med 357 (2007), 266–281.
Narula, N., Marshall, J.K., Management of inflammatory bowel disease with vitamin D: beyond bone health. J Crohns Colitis 6 (2012), 397–404.
Barbalho, S.M., Goulart, R.A., Gasparini, R.G., Associations between inflammatory bowel diseases and vitamin D. Crit Rev Food Sci Nutr 59 (2019), 1347–1356.
Sherman, M.H., Yu, R.T., Engle, D.D., et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159 (2014), 80–93.
Abramovitch, S., Dahan-Bachar, L., Sharvit, E., et al. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut 60 (2011), 1728–1737.
Johnson, L.A., Sauder, K.L., Rodansky, E.S., et al. CARD-024, a vitamin D analog, attenuates the pro-fibrotic response to substrate stiffness in colonic myofibroblasts. Exp Mol Pathol 93 (2012), 91–98.
Ardizzone, S., Cassinotti, A., Trabattoni, D., et al. Immunomodulatory effects of 1,25-dihydroxyvitamin D3 on TH1/TH2 cytokines in inflammatory bowel disease: an in vitro study. Int J Immunopathol Pharmacol 22 (2009), 63–71.
Boonstra, A., Barrat, F.J., Crain, C., et al. 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 167 (2001), 4974–4980.
Mahon, B.D., Wittke, A., Weaver, V., et al. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem 89 (2003), 922–932.
Cantorna, M.T., Munsick, C., Bemiss, C., et al. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 130 (2000), 2648–2652.
Wada, K., Tanaka, H., Maeda, K., et al. Vitamin D receptor expression is associated with colon cancer in ulcerative colitis. Oncol Rep 22 (2009), 1021–1025.
Yu, S., Bruce, D., Froicu, M., et al. Failure of T cell homing, reduced CD4/CD8alphaalpha intraepithelial lymphocytes, and inflammation in the gut of vitamin D receptor KO mice. Proc Natl Acad Sci U S A 105 (2008), 20834–20839.
Ananthakrishnan, A.N., Cagan, A., Gainer, V.S., et al. Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn's disease. Inflamm Bowel Dis 19 (2013), 1921–1927.
Jorgensen, S.P., Agnholt, J., Glerup, H., et al. Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther 32 (2010), 377–383.
Caprilli, R., Gassull, M.A., Escher, J.C., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 55:Suppl 1 (2006), i36–i58.
Regueiro, M., Feagan, B.G., Zou, B., et al. Infliximab reduces endoscopic, but not clinical, recurrence of Crohn's disease after ileocolonic resection. Gastroenterology 150 (2016), 1568–1578.
Rungoe, C., Langholz, E., Andersson, M., et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut 63 (2014), 1607–1616.
D'Haens, G.R., Vermeire, S., Van Assche, G., et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 135 (2008), 1123–1129.
Hanauer, S.B., Korelitz, B.I., Rutgeerts, P., et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 127 (2004), 723–729.
Mowat, C., Arnott, I., Cahill, A., et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. Lancet Gastroenterol Hepatol 1 (2016), 273–282.
De Cruz, P., Kamm, M.A., Hamilton, A.L., et al. Crohn's disease management after intestinal resection: a randomised trial. Lancet 385 (2015), 1406–1417.
Regueiro, M., Schraut, W., Baidoo, L., et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 136 (2009), 441–450.
Dawson-Hughes, B., Heaney, R.P., Holick, M.F., et al. Estimates of optimal vitamin D status. Osteoporosis Int 16 (2005), 713–716.
Gallagher, J.C., Smith, L.M., Yalamanchili, V., Incidence of hypercalciuria and hypercalcemia during vitamin D and calcium supplementation in older women. Menopause 21 (2014), 1173–1180.
Hausler, D., Torke, S., Weber, M.S., High-dose vitamin D-mediated hypercalcemia as a potential risk factor in central nervous system demyelinating disease. Front Immunol, 11, 2020, 301.
Best, W.R., Becktel, J.M., Singleton, J.W., et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70 (1976), 439–444.
Brooks, R., EuroQol: the current state of play. Health Policy 37 (1996), 53–72.
Irvine, E.J., Feagan, B., Rochon, J., et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 106 (1994), 287–296.
Ware, J.E. Jr., Sherbourne, C.D., The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30 (1992), 473–483.
Ma, C., Gecse, K.B., Duijvestein, M., et al. Reliability of endoscopic evaluation of postoperative recurrent Crohn's disease. Clin Gastroenterol Hepatol 18 (2020), 2139–2141.
Jaspers, S.L., Duijvestein, M., van der Meulen-de Jong, A.E., et al. Recurrence rate and risk factors of postoperative Crohn's disease. Gastroenterology 148 (2015), S255–S256.
Satsangi, J., Silverberg, M.S., Vermeire, S., et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55 (2006), 749–753.
Peyrin-Biroulet, L., Reinisch, W., Colombel, J.F., et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 63 (2014), 88–95.
Raftery, T., Martineau, A.R., Greiller, C.L., et al. Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn's disease: results from a randomised double-blind placebo-controlled study. United European Gastroenterol J 3 (2015), 294–302.
Gubatan, J., Mitsuhashi, S., Zenlea, T., et al. Low serum vitamin D during remission increases risk of clinical relapse in patients with ulcerative colitis. Clin Gastroenterol Hepatol 15 (2017), 240–246.e1.
Narula, N., Cooray, M., Anglin, R., et al. Impact of high-dose vitamin D3 supplementation in patients with Crohn's disease in remission: a pilot randomized double-blind controlled study. Dig Dis Sci 62 (2017), 448–455.
Reese, G.E., Nanidis, T., Borysiewicz, C., et al. The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies. Int J Colorectal Dis 23 (2008), 1213–1221.
Bernell, O., Lapidus, A., Hellers, G., Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 231 (2000), 38–45.
Bossuyt, P., Debeuckelaere, C., Ferrante, M., et al. Risk stratification for surgery in stricturing ileal Crohn's disease: the BACARDI risk model. J Crohns Colitis 12 (2018), 32–38.
Van Assche, G., Dignass, A., Reinisch, W., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 4 (2010), 63–101.
Sachar, D.B., Lemmer, E., Ibrahim, C., et al. Recurrence patterns after first resection for stricturing or penetrating Crohn's disease. Inflamm Bowel Dis 15 (2009), 1071–1075.
Bischoff-Ferrari, H.A., Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. Adv Exp Med Biol 624 (2008), 55–71.
Garg, M., Rosella, O., Rosella, G., et al. Evaluation of a 12-week targeted vitamin D supplementation regimen in patients with active inflammatory bowel disease. Clin Nutr 37 (2018), 1375–1382.
Bolland, M.J., Grey, A.B., Ames, R.W., et al. The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency. Am J Clin Nutr 86 (2007), 959–964.
